key: cord-0821538-se7fv60m
authors: Izumo, Takehiro; Kuse, Naoyuki; Awano, Nobuyasu; Tone, Mari; Sakamoto, Keita; Takada, Kohei; Muto, Yutaka; Fujimoto, Kazushi; Saiki, Ayae; Ito, Yu; Matsumoto, Haruko; Inomata, Minoru
title: Clinical impact of combination therapy with baricitinib, remdesivir, and dexamethasone in patients with severe COVID-19
date: 2021-08-10
journal: Respir Investig
DOI: 10.1016/j.resinv.2021.07.004
sha: 8acada2e735693707d9ee9c55ec347f00817140d
doc_id: 821538
cord_uid: se7fv60m

BACKGROUND: Coronavirus disease 2019 (COVID-19) has spread worldwide and is also an important disease in Japan. Thus, the optimal treatment strategy for severe COVID-19 should be established urgently. The effects of combination treatment with baricitinib—a Janus kinase inhibitor, remdesivir, and dexamethasone (BRD) are unknown. METHODS: Patients who received combination therapy with BRD at the Japanese Red Cross Medical Center were enrolled in the study. All patients received baricitinib (≤14 d), remdesivir (≤10 d), and dexamethasone (≤10 d). The efficacy and adverse events were evaluated. RESULTS: In total, 44 patients with severe COVID-19 were enrolled in this study. The 28-d mortality rate was low at 2.3 % (1/44 patients). The need for invasive mechanical ventilation was avoided in most patients (90 %, 17/19 patients). Patients who received BRD therapy had a median hospitalization duration of 11 d, time to recovery of 9 d, duration of intensive care unit stay of 6 d, duration of invasive mechanical ventilation of 5 d, and duration of supplemental oxygen therapy of 5 d. Adverse events occurred in 15 patients (34 %). Liver dysfunction, thrombosis, iliopsoas hematoma, renal dysfunction, ventilator-associated pneumonia, infective endocarditis, and herpes zoster occurred in 11 %, 11 %, 2 %, 2 %, 2 %, 2 %, and 2 % of patients, respectively. CONCLUSIONS: Combination therapy with BRD was effective in treating severe COVID-19, and the incidence rate of adverse events was low. The results of the present study are encouraging; however, further randomized clinical studies are needed.

ventilator-associated pneumonia, infective endocarditis, and herpes zoster occurred in 11 %, 11 %, 2 %, 33 2 %, 2 %, 2 %, and 2 % of patients, respectively.

Conclusions: Combination therapy with BRD was effective in treating severe and 

However, the therapeutic effect of each drug alone is not satisfactory. Recently, the results of a 47 combination therapy with remdesivir and baricitinib were reported in the Adaptive COVID-19 Treatment

Trial 2 (ACTT-2) study [4] . Baricitinib, an orally administered selective inhibitor of Janus kinase (JAK) 1 49 and 2, is considered a potential therapeutic agent against SARS-CoV-2 [5, 6] . Baricitinib inhibits the 50 intracellular signaling pathway of cytokines that are known to have elevated levels in severe COVID-19, 51 including interleukin-2, interleukin-6, interleukin-10, interferon-γ, and granulocyte-macrophage 52 colony-stimulating factor; suppresses SARS-CoV-2 through the impairment of AP2-associated protein 53 kinase 1 and the prevention of SARS-CoV-2 cellular entry and infectivity; and improves lymphocyte The diagnosis of COVID-19 was confirmed via polymerase chain reaction (PCR) for SARS-CoV-2 73 using sputum or nasopharyngeal swab samples. SARS-CoV-2 RNA was detected using TaqMan one-step 74 real-time PCR kits (QIAGEN, Co., Ltd., Hilden, Germany). In accordance with the National Institutes of 75 Health classification criteria, COVID-19 patients were classified into four categories as follows: 1) mild 76 illness group, patients with different signs and symptoms of COVID-19 except for shortness of breath, 7 dyspnea, or abnormal chest imaging finding; 2) moderate illness group, patients with lower respiratory 78 diseases diagnosed based on clinical assessment or imaging examination and a blood oxygen saturation 79 level (SpO 2 ) ≥ 94 % in room air at sea level; 3) severe illness group, patients with respiratory rate > 30 80 breaths per minute, SpO 2 < 94 % in room air at sea level, arterial partial pressure of oxygen to fraction of 81 inspired oxygen ratio < 300 Torr, or lung infiltrates > 50 %; and 4) critical illness group, patients with 82 respiratory failure, septic shock, and/or multiorgan dysfunction [9].

From December 2020 to January 2021, patients who were severely or critically ill with COVID-19 84 without severe renal dysfunction (with an estimated glomerular filtration rate [eGFR] < 30 mL/min) on 85 admission were consecutively enrolled in this study.

Remdesivir was administered intravenously at a 200-mg loading dose on day 1, followed by 100 mg 89 from days 2 to 5 (without invasive mechanical ventilation) or days 2 to 10 (with invasive mechanical 90 ventilation) [10] . Oral or intravenous dexamethasone was administered at a dose of 6 mg daily for up to 

In total, 44 patients with severe COVID-19 were enrolled in this study.

The clinical characteristics of the patients at baseline are presented in Table 1 . Briefly, the median 

The clinical laboratory data of the patients at baseline are presented in Table 2 . Briefly, the median white 117 blood cell (WBC) count was 6100/mm 3 (IQR: 5500-7500/mm 3 ), lymphocyte count was 840/mm 3 (IQR:

118 530-1085/mm 3 ), and eosinophil count was 0/mm 3 (IQR: 0-10/mm 3 ). There were no significant increases 119 in WBC count or decreases in lymphocyte and eosinophil counts, despite the marked decrease in median 120 eosinophil count to 0. The median C-reactive protein and ferritin levels increased to 7.4 mg/mL and 635 121 ng/mL, respectively.

The patient outcomes are presented in Table 3 

The adverse events are presented in Table 4 and were reported in accordance with CTCAE version 5.0.

Adverse events occurred in total 15 patients (34 %), wherein liver dysfunction occurred in 11 % of 130 patients, thrombosis in 11 %, iliopsoas hematoma in 2 %, renal dysfunction in 2 %, ventilator-associated 10 pneumonia in 2 %, infective endocarditis in 2 %, and herpes zoster in 2 %.

To the best of our knowledge, this is the first study on the efficacy and safety of BRD combination 135 therapy in patients with severe COVID-19 in clinical practice. In this study, BRD therapy was found to be 136 highly effective, with acceptable adverse events, against severe COVID-19. 

According to the ACTT-1 study, the secondary endpoint of mortality by day 15 was 6.7 % in patients 142 receiving remdesivir compared to 11.9 % in patients receiving placebo, whereas that by day 29 was 143 11.4 % and 15.2 % in the two groups, respectively, although the differences were not statistically 

In the present study, BRD therapy was found to be highly effective, with 2.3 % mortality rate and 90 % 155 of patients not requiring invasive mechanical ventilation. In addition, 96 % of patients could be extubated 156 from invasive mechanical ventilation. The length of ICU stay is a critical problem in patients with severe 157 COVID-19; however, in this study, the median duration of ICU stay was as short as 6 d among patients 158 receiving BRD therapy-this might be advantageous in clinical practice.

The incidence of adverse events was 34 %. Combined administration of the two types of 160 immunomodulators, dexamethasone and baricitinib, did not cause major problems, which indicates that 161 combination therapy should be seriously considered for COVID-19 treatment in clinical practice.

According to the ACTT-2 trial, despite concerns regarding immunosuppression, secondary infections, and 163 thrombosis with the use of JAK inhibitors, the addition of baricitinib was not associated with a 164 significantly higher incidence of adverse or thromboembolic events [4] . In fact, patients who received 165 baricitinib plus remdesivir had significantly lower incidence rates of adverse events, adverse events 166 leading to discontinuation of the trial drug, serious adverse events, serious adverse events with a fatal 12 outcome, and infection-related adverse events than patients who received remdesivir alone. The 168 consistently lower incidence rate of adverse events with baricitinib monotherapy may be related to its 169 ability to reduce inflammatory lung injury and improve lymphocyte counts, its antiviral properties, or its 

The present study had several limitations. First, the study was conducted at a single center, and only 175 few patients were included. Second, a control group of patients with severe COVID-19 receiving the 176 standard of care was not included in this study. In clinical practice, setting a control group was difficult 177 because of patient care. Moreover, the standard of care differed depending on the season, variants, and 178 medical supply system. Therefore, even if we tried propensity matching, it was difficult to perform a 179 comparative study. Third, the study was conducted without preparing a special environment as much as 

The authors have no conflict of interest to declare in relation to this work. (90) Extubation from invasive mechanical ventilation, no./total no. of patients (%) 24/25 (96) Hospitalization duration, days, median (IQR) 11 (7-17) Time to recovery, days, median (IQR) 9 (6-15) Duration of intensive care unit stay, days, median (IQR) 6 (4-9)

Duration of invasive mechanical ventilation, days, median (IQR) 5 (4-8)

Duration of supplemental oxygen therapy, days, median (IQR) 5 (2-8) IQR, interquartile range 250 251 22 (2) Renal dysfunction 1/44 (2) Ventilator-associated pneumonia 1/44 (2) Infective endocarditis 1/44 (2) Herpes zoster 1/44 (2) 253 254 255 256

The Japanese Respiratory Society

Potential Conflict of Interest Disclosure Statement

A novel coronavirus from patients with 211 pneumonia in china

Remdesivir for 213 the treatment of covid-19 -Final report

Dexamethasone in hospitalized patients with covid-19

Baricitinib 217 plus remdesivir for hospitalized adults with covid-19

Covid-19: 219 Combining antiviral and anti-inflammatory treatments

Baricitinib as potential 221 treatment for 2019-ncov acute respiratory disease

Mechanism 223 of baricitinib supports artificial intelligence-predicted testing in covid-19 patients

Serum kl-6 level is a useful 229 biomarker for evaluating the severity of coronavirus disease

Remdesivir in adults with severe covid-19: 231 A randomised, double-blind, placebo-controlled, multicentre trial

Investigation of the freely available easy-to-use software 'ezr' for medical statistics

Severe covid-19

Neutralizing 236 monoclonal antibodies for treatment of covid-19

Lymphocyte count, per mm 3 , median (IQR)

Eosinophil count, per mm 3 , median (IQR)

AST level, U/L, median (IQR)

ALT level, U/L, median (IQR)

LDH level, U/L, median (IQR)

CK level, U/L, median (IQR)

BUN level, mg/dL, median (IQR)

Cre level, mg/dL, median (IQR)

Zn level, μg/dL, median (IQR)

Alb level, μg/dL, median (IQR)

Ferritin level, ng/mL, median (IQR)

PCT level, ng/mL

D-dimer level, μg/dL, median (IQR)

sIL-2R level, U/mL, median (IQR)

KL-6 level, U/mL, median (IQR)

WBC, white blood cell

alanine 244 aminotransferase; LDH, lactate dehydrogenase; CK, creatinine kinase; BUN, blood urea nitrogen

245 creatinine; eGFR, estimated glomerular filtration rate

Author's names: Takehiro Izumo*, Naoyuki Kuse, Nobuyasu Awano, Mari Tone, Keita Sakamoto, Kohei Takada, Yutaka Muto, Kazushi Fujimoto, Ayae Saiki, Yu Ito, Haruko Matsumoto, Minoru Inomata Manuscript Title: Clinical impact of combination therapy with baricitinib, remdesivir, and dexamethasone in patients with severe COVID-19All authors are required to disclose any COI within 3 calendar years preceding the current year, prior to the submission of any manuscript in the subject matter of which any company, entity, or organization has an interest.

No If Yes: List the name(s) of authors and commercial entity(ies) and use as much space as necessary